Medicare should link drug payments to value and should consider including drugs in bundled payments, researchers said Oct. 26 at a briefing.
Mark McClellan, director of the Duke-Margolis Center for Health Policy at Duke University in Durham, N.C., said Medicare should determine drug payments by looking at evidence that shows how well a drug will work for a particular patient. McClellan is a former administrator of the Centers for Medicare & Medicaid Services.
Meanwhile, Gerard Anderson, a professor at Johns Hopkins Bloomberg School of Public Health, said Part D drugs should be included in bundled payments, which combine payments for an episode of care into a single payment.
The Alliance for Health Reform held the briefing on Medicare and prescription drug prices because “paying for drugs for Medicare enrollees is a major focus of Congress, CMS, candidates for office and the health industry generally,” Karl Eisenhower, director of communications and special projects at the alliance, told me.
A spokesman for the Biotechnology Innovation Organization (BIO) told me that “while value-based reimbursement arrangements can be one promising mechanism to recognize the value of innovative therapies, they must be considered thoughtfully on a case-by-case basis and must eschew a limited range of approaches to avoid disrupting patient care or stalling innovation in the long term.”
BIO member companies “are committed to working collaboratively with payers, healthcare providers, patients, and policy makers to explore the broad range of innovative approaches for realizing the full potential of 21st century medicines to maximize patient benefit and drive ‘smarter spending’ within the healthcare system,” the spokesman said. He said examples of these innovative approaches include novel value-based and outcomes-based contracting arrangements and alternative financing and payment mechanisms.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)